Loading company
Akebia Therapeutics, Inc.
AKBA · Nasdaq · ·
Next earnings: November 9, 2026
$0.89-1.0%Sep 29 close
- 1M
- +1.3%
- 6M
- -32.6%
- 1Y
- -67.4%
- 5Y
- -70.7%
AKBA · Nasdaq · ·
Next earnings: November 9, 2026
$0.89-1.0%Sep 29 close
Akebia Therapeutics, Inc. is scheduled to report next on November 9, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $49.1M | $62.5M | -21.36% |
| Profit | -$8.9M | $247K | -3,706.48% |
| Profit per share | -$0.03 | $0.00 | — |
| Free Cash Flow | $2.4M | $22.2M | -88.99% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“We’re pleased with Vafseo’s continued sequential revenue growth this quarter, as well as the recently announced positive VOICE trial results for the primary endpoint, which marks an important step in our ultimate goal of making Vafseo standard of care for the treatment of anemia in patients on dialysis,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Akebia Therapeutics, Inc.’s Item 2.02 8-K filed August 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Akebia Therapeutics, Inc. has no earnings call transcript available.